Matches in SemOpenAlex for { <https://semopenalex.org/work/W1797553927> ?p ?o ?g. }
- W1797553927 abstract "Hirsutism occurs in 5% to 10% of women of reproductive age when there is excessive terminal hair growth in androgen-sensitive areas (male pattern). It is a distressing disorder with a major impact on quality of life. The most common cause is polycystic ovary syndrome. There are many treatment options, but it is not clear which are most effective.To assess the effects of interventions (except laser and light-based therapies alone) for hirsutism.We searched the Cochrane Skin Group Specialised Register, CENTRAL (2014, Issue 6), MEDLINE (from 1946), EMBASE (from 1974), and five trials registers, and checked reference lists of included studies for additional trials. The last search was in June 2014.Randomised controlled trials (RCTs) in hirsute women with polycystic ovary syndrome, idiopathic hirsutism, or idiopathic hyperandrogenism.Two independent authors carried out study selection, data extraction, 'Risk of bias' assessment, and analyses.We included 157 studies (sample size 30 to 80) comprising 10,550 women (mean age 25 years). The majority of studies (123/157) were 'high', 30 'unclear', and four 'low' risk of bias. Lack of blinding was the most frequent source of bias. Treatment duration was six to 12 months. Forty-eight studies provided no usable or retrievable data, i.e. lack of separate data for hirsute women, conference proceedings, and losses to follow-up above 40%.Primary outcomes, 'participant-reported improvement of hirsutism' and 'change in health-related quality of life', were addressed in few studies, and adverse events in only half. In most comparisons there was insufficient evidence to determine if the number of reported adverse events differed. These included known adverse events: gastrointestinal discomfort, breast tenderness, reduced libido, dry skin (flutamide and finasteride); irregular bleeding (spironolactone); nausea, diarrhoea, bloating (metformin); hot flushes, decreased libido, vaginal dryness, headaches (gonadotropin-releasing hormone (GnRH) analogues)).Clinician's evaluation of hirsutism and change in androgen levels were addressed in most comparisons, change in body mass index (BMI) and improvement of other clinical signs of hyperandrogenism in one-third of studies.The quality of evidence was moderate to very low for most outcomes.There was low quality evidence for the effect of two oral contraceptive pills (OCPs) (ethinyl estradiol + cyproterone acetate versus ethinyl estradiol + desogestrel) on change from baseline of Ferriman-Gallwey scores. The mean difference (MD) was -1.84 (95% confidence interval (CI) -3.86 to 0.18).There was very low quality evidence that flutamide 250 mg, twice daily, reduced Ferriman-Gallwey scores more effectively than placebo (MD -7.60, 95% CI -10.53 to -4.67 and MD -7.20, 95% CI -10.15 to -4.25). Participants' evaluations in one study with 20 participants confirmed these results (risk ratio (RR) 17.00, 95% CI 1.11 to 259.87).Spironolactone 100 mg daily was more effective than placebo in reducing Ferriman-Gallwey scores (MD -7.69, 95% CI -10.12 to -5.26) (low quality evidence). It showed similar effectiveness to flutamide in two studies (MD -1.90, 95% CI -5.01 to 1.21 and MD 0.49, 95% CI -1.99 to 2.97) (very low quality evidence), as well as to finasteride in two studies (MD 1.49, 95% CI -0.58 to 3.56 and MD 0.40, 95% CI -1.18 to 1.98) (low quality evidence).Although there was very low quality evidence of a difference in reduction of Ferriman-Gallwey scores for finasteride 5 mg to 7.5 mg daily versus placebo (MD -5.73, 95% CI -6.87 to -4.58), it was unlikely it was clinically meaningful. These results were reinforced by participants' assessments (RR 2.06, 95% CI 0.99 to 4.29 and RR 11.00, 95% CI 0.69 to 175.86). However, finasteride showed inconsistent results in comparisons with other treatments, and no firm conclusions could be reached.Metformin demonstrated no benefit over placebo in reduction of Ferriman-Gallwey scores (MD 0.05, 95% CI -1.02 to 1.12), but the quality of evidence was low. Results regarding the effectiveness of GnRH analogues were inconsistent, varying from minimal to important improvements.We were unable to pool data for OCPs with cyproterone acetate 20 mg to 100 mg due to clinical and methodological heterogeneity between studies. However, addition of cyproterone acetate to OCPs provided greater reductions in Ferriman-Gallwey scores.Two studies, comparing finasteride 5 mg and spironolactone 100 mg, did not show differences in participant assessments and reduction of Ferriman-Gallwey scores (low quality evidence). Ferriman-Gallwey scores from three studies comparing flutamide versus metformin could not be pooled (I² = 62%). One study comparing flutamide 250 mg twice daily with metformin 850 mg twice daily for 12 months, which reached a higher cumulative dosage than two other studies evaluating this comparison, showed flutamide to be more effective (MD -6.30, 95% CI -9.83 to -2.77) (very low quality evidence). Data showing reductions in Ferriman-Gallwey scores could not be pooled for four studies comparing finasteride with flutamide as the results were inconsistent (I² = 67%).Studies examining effects of hypocaloric diets reported reductions in BMI, but which did not result in reductions in Ferriman-Gallwey scores. Although certain cosmetic measures are commonly used, we did not identify any relevant RCTs.Treatments may need to incorporate pharmacological therapies, cosmetic procedures, and psychological support. For mild hirsutism there is evidence of limited quality that OCPs are effective. Flutamide 250 mg twice daily and spironolactone 100 mg daily appeared to be effective and safe, albeit the evidence was low to very low quality. Finasteride 5 mg daily showed inconsistent results in different comparisons, therefore no firm conclusions can be made. As the side effects of antiandrogens and finasteride are well known, these should be accounted for in any clinical decision-making. There was low quality evidence that metformin was ineffective for hirsutism and although GnRH analogues showed inconsistent results in reducing hirsutism they do have significant side effects.Further research should consist of well-designed, rigorously reported, head-to-head trials examining OCPs combined with antiandrogens or 5α-reductase inhibitor against OCP monotherapy, as well as the different antiandrogens and 5α-reductase inhibitors against each other. Outcomes should be based on standardised scales of participants' assessment of treatment efficacy, with a greater emphasis on change in quality of life as a result of treatment." @default.
- W1797553927 created "2016-06-24" @default.
- W1797553927 creator A5028843574 @default.
- W1797553927 creator A5045912789 @default.
- W1797553927 creator A5046465972 @default.
- W1797553927 creator A5066448929 @default.
- W1797553927 date "2015-04-28" @default.
- W1797553927 modified "2023-09-27" @default.
- W1797553927 title "Interventions for hirsutism (excluding laser and photoepilation therapy alone)" @default.
- W1797553927 cites W105897893 @default.
- W1797553927 cites W119992591 @default.
- W1797553927 cites W126639299 @default.
- W1797553927 cites W128087654 @default.
- W1797553927 cites W1483604492 @default.
- W1797553927 cites W1537972189 @default.
- W1797553927 cites W1552337395 @default.
- W1797553927 cites W1582550852 @default.
- W1797553927 cites W1606257794 @default.
- W1797553927 cites W160723224 @default.
- W1797553927 cites W1627441187 @default.
- W1797553927 cites W1774724565 @default.
- W1797553927 cites W1797553927 @default.
- W1797553927 cites W180816057 @default.
- W1797553927 cites W1843165220 @default.
- W1797553927 cites W1862433166 @default.
- W1797553927 cites W1869253919 @default.
- W1797553927 cites W1897982282 @default.
- W1797553927 cites W1906055651 @default.
- W1797553927 cites W1954184248 @default.
- W1797553927 cites W1963628647 @default.
- W1797553927 cites W1964561776 @default.
- W1797553927 cites W1965747471 @default.
- W1797553927 cites W1965887584 @default.
- W1797553927 cites W1966000915 @default.
- W1797553927 cites W1966417579 @default.
- W1797553927 cites W1966517101 @default.
- W1797553927 cites W1966680031 @default.
- W1797553927 cites W1967469845 @default.
- W1797553927 cites W1967738319 @default.
- W1797553927 cites W1967759372 @default.
- W1797553927 cites W1967770926 @default.
- W1797553927 cites W1968984253 @default.
- W1797553927 cites W1970740177 @default.
- W1797553927 cites W1970753372 @default.
- W1797553927 cites W1971779058 @default.
- W1797553927 cites W1973708701 @default.
- W1797553927 cites W1974442564 @default.
- W1797553927 cites W1974799218 @default.
- W1797553927 cites W1974859446 @default.
- W1797553927 cites W1976059259 @default.
- W1797553927 cites W1976973160 @default.
- W1797553927 cites W1977287851 @default.
- W1797553927 cites W1978508415 @default.
- W1797553927 cites W1979519935 @default.
- W1797553927 cites W1979769331 @default.
- W1797553927 cites W1980110137 @default.
- W1797553927 cites W1981081060 @default.
- W1797553927 cites W1984067141 @default.
- W1797553927 cites W1984195284 @default.
- W1797553927 cites W1985028710 @default.
- W1797553927 cites W1985527255 @default.
- W1797553927 cites W1986536000 @default.
- W1797553927 cites W1987257219 @default.
- W1797553927 cites W1987625180 @default.
- W1797553927 cites W1988248535 @default.
- W1797553927 cites W1988477927 @default.
- W1797553927 cites W1989429105 @default.
- W1797553927 cites W1989744571 @default.
- W1797553927 cites W1989790361 @default.
- W1797553927 cites W1990268466 @default.
- W1797553927 cites W1990719778 @default.
- W1797553927 cites W1991430814 @default.
- W1797553927 cites W1992253895 @default.
- W1797553927 cites W1992614785 @default.
- W1797553927 cites W1992735079 @default.
- W1797553927 cites W1994216334 @default.
- W1797553927 cites W1994494139 @default.
- W1797553927 cites W1994646644 @default.
- W1797553927 cites W1994805060 @default.
- W1797553927 cites W1995813378 @default.
- W1797553927 cites W1995813644 @default.
- W1797553927 cites W1996742630 @default.
- W1797553927 cites W1997867063 @default.
- W1797553927 cites W1998630269 @default.
- W1797553927 cites W1998798663 @default.
- W1797553927 cites W2000869218 @default.
- W1797553927 cites W2001005057 @default.
- W1797553927 cites W2001380683 @default.
- W1797553927 cites W2003741958 @default.
- W1797553927 cites W2004724302 @default.
- W1797553927 cites W2004938885 @default.
- W1797553927 cites W2005664667 @default.
- W1797553927 cites W2006033053 @default.
- W1797553927 cites W2006659599 @default.
- W1797553927 cites W2007718961 @default.
- W1797553927 cites W2008236525 @default.
- W1797553927 cites W2008252901 @default.
- W1797553927 cites W2009557657 @default.
- W1797553927 cites W2010702574 @default.
- W1797553927 cites W2011658030 @default.